Entera Bio Ltd. (ENTX)
NASDAQ: ENTX · IEX Real-Time Price · USD
1.710
-0.050 (-2.84%)
At close: Jul 2, 2024, 4:00 PM
1.890
+0.180 (10.53%)
After-hours: Jul 2, 2024, 5:21 PM EDT
Entera Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
17
Market Cap
61.25M USD
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 134.00K | -437.00K | -76.53% |
| Dec 31, 2021 | 571.00K | 206.00K | 56.44% |
| Dec 31, 2020 | 365.00K | 129.00K | 54.66% |
| Dec 31, 2019 | 236.00K | -264.00K | -52.80% |
| Dec 31, 2018 | 500.00K | - | - |
| Dec 31, 2017 | 0 | - | - |
| Dec 31, 2016 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MDxHealth | 75.33M |
| Burning Rock Biotech | 72.30M |
| Theratechnologies | 57.85M |
| MSP Recovery | 9.71M |
| Genelux | 8.00K |
| Benitec Biopharma | 7.00K |
ENTX News
- 6 weeks ago - Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member - GlobeNewsWire
- 7 weeks ago - Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024 - GlobeNewsWire
- 7 weeks ago - Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 3 months ago - Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research - GlobeNewsWire
- 3 months ago - Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months - GlobeNewsWire
- 3 months ago - Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome - GlobeNewsWire
- 4 months ago - Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates - GlobeNewsWire
- 4 months ago - Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire